Seno’s breast cancer imaging system will help physicians differentiate between benign and malignant breast lesions using non-invasive OA/US technology, and provides information on breast lesions in real time
The Imagio System was approved by the US FDA in 2021. (Credit: Seno Medical)
US-based medical imaging company Seno Medical has signed an exclusive distribution agreement with Singapore-based AI-based software company Genetik.
Under the terms of the agreement, Genetik will market sell and service Seno’s imagio opto-acoustic/ultrasound (OA/US) breast imaging system.
It is first distribution agreement for Seno, and allows Genetik to regionally distribute the Imagio System in Singapore.
Seno said that its breast cancer imaging system is said to help physicians differentiate between benign and malignant breast lesions using non-invasive OA/US technology.
It provides information on breast lesions in real time, which helps healthcare providers to characterise masses that may, or may not require more invasive diagnostic evaluation.
Genetik CEO VB Balrai Singh said: “We are proud to work with innovative and highly accurate technologies that can change the standard of care for patients.
“We look forward to representing this state-of-the-art product for diagnosing breast cancer – the only global FDA-approved technology based on photoacoustic fused with ultrasound.”
According to the company, false-positive diagnostic assessments result in unwanted breast biopsy procedures which cost billions of dollars each year.
Seno said that its Imagio technology will significantly reduce the costs associated with breast biopsy procedures due to false-positive assessment.
The OA/US system combines laser optics and grayscale ultrasound to offer a fused functional, morphological, and anatomical breast imaging.
It also helps radiologists to confirm or rule out malignancy by detecting the appearance or absence of angiogenesis and hypoxia, which indicate cancer.
In addition to the novel imaging, it also offers an artificial intelligence (AI) decision-support tool (SenoGram) to help physicians interpret the new images, said Seno.
The US Food and Drug Administration (FDA) approved Imagio System in 2021, and has granted a supplemental PMA approval for the device in June 2022.
Seno Medical president and CEO Tom Umbel said: “We are thrilled to be partnering with a reputable organization such as Genetik to stimulate commercial adoption of the Imagio System into Southeast Asia.
“This agreement represents a major milestone for Seno Medical and the continued acceptance and adoption of our new fusion modality in breast imaging.”